真实世界中抗真菌预防在AML巩固治疗期间预防侵袭性曲霉病的作用:SEIFEM 2016研究
该多中心回顾性研究纳入2588例接受强化巩固治疗的AML患者,侵袭性曲霉病(IA)发生率为2.2%,接受抗真菌预防(AP)者IA发生率1.5%显著低于未预防者2.9%(P=0.01)。AP似可预防巩固期IA,但老年及接受大剂量阿糖胞苷者死亡率仍不可忽视。
要点
- AML巩固期IA总发生率2.2%,AP组1.5%低于无AP组2.9%(P=0.01)。
- 预防组一线治疗良好应答率73%,显著高于未预防组29%(P=0.001)。
- 年龄≥60岁及大剂量阿糖胞苷独立影响结局,需关注老年患者。
核心结论
- 在本真实世界研究中,抗真菌预防似可预防AML巩固治疗期间IA的发生。
- 尽管IA发生率低,但老年患者及接受大剂量阿糖胞苷者死亡率不可忽视。
研究设计与样本
- 多中心意大利回顾性研究,收集2011至2015年成人及儿童AML患者巩固治疗期间IA病例。
- 共纳入2588例患者,其中1137例未接受AP,1451例接受AP。
主要发现
- 2588例中56例(2.2%)发生IA,包括43例 probable(1.7%)和13例 proven(0.5%)。
- 无AP组IA发生率2.9%(34/1137),AP组1.5%(22/1451),P=0.01。
- 需治疗人数计算显示平均71例患者接受AP(而非无AP)可额外避免1例IA。
- 初始抗真菌治疗为抢先治疗者36例(64%),靶向治疗者20例(36%)。
- 一线治疗良好应答26例(46%),AP组16/22(73%)高于无AP组10/34(29%),P=0.001。
关键数值与推荐
- 第120天总死亡率为16%,IA归因死亡率为9%。
- 多因素分析中年龄≥60岁(OR=12.46,95%CI=1.13-136.73;P=0.03)和大剂量阿糖胞苷治疗(OR=10.56,95%CI=1.95-116.74;P=0.04)独立影响结局。
临床怎么用
- 在AML强化巩固治疗期间可考虑抗真菌预防以降低IA风险。
- 对年龄≥60岁或接受大剂量阿糖胞苷的患者应加强IA监测与风险管理。
局限性
- 本研究为回顾性多中心研究,可能存在选择偏倚与未测量混杂。
- 作者建议进一步开展前瞻性研究,尤其在老年及接受大剂量阿糖胞苷的患者中验证并识别需AP的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy. METHODS: Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and 2015, were retrospectively collected in a multicentre Italian study. RESULTS: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P = 0.01). Number-needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P = 0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age ≥60 years (OR = 12.46, 95% CI = 1.13-136.73; P = 0.03) and high-dose cytarabine treatment (OR = 10.56, 95% CI = 1.95-116.74; P = 0.04) independently affected outcome. CONCLUSIONS: In our experience, AP appears to prevent IA from occurring during consolidation. However, although the incidence of IA was low, mortality was not negligible among older patients. Further prospective studies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data and to identify subsets of individuals who may require AP.
引用
- Del Principe MI, Dragonetti G, Verga L, et al. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. J Antimicrob Chemother. 2019. PMID: 30649413. doi:10.1093/jac/dky550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。